$63.98
LGD 4033 + Ostarine tablets is offered in 2 variants: 20mg per tablet for 27 tablets, totaling 540mg and 20mg per tablet for 54 tablets, totaling 1080mg.
LGD 4033 is a novel nonsteroidal oral selective androgen receptor modulator being investigated as a potential treatment for muscle dystrophy and osteoporosis. Recent studies showed that LGD 4033 had a positive effect on muscle tissue in ovariectomized rats. The LGD treatment resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.
| LGD-4033 | |
| CAS Number | 1165910-22-4 |
| Molar Mass | 338.253 g·mol−1 |
| Chemical Formula | C14H12F6N2O |
| IUPAC Name | 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| Ostarine | |
| CAS Number | 1202044-20-9 |
| Molar Mass | 389.33g/mol-1 |
| Chemical Formula | C19H10D4F3N3O3 |
| IUPAC Name | 3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide |
onpeptides.com